Get the Stockscreener App
2.53
8.33%
-0.23
Pre-market:
2.68
0.15
+5.93%
Codexis Inc stock is traded at $2.53, with a volume of 689.54K.
It is down -8.33% in the last 24 hours and down -38.29% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.76
Open:
$2.74
24h Volume:
689.54K
Relative Volume:
0.88
Market Cap:
$209.58M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-2.2793
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-7.33%
1M Performance:
-38.29%
6M Performance:
-8.99%
1Y Performance:
-25.15%
1-Day Range:
$2.515
$2.7837
1-Week Range:
$2.515
$2.845
52-Week Range:
$2.47
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.53 | 209.58M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis sees $261,350 stock acquisition by Opaleye management By Investing.com - Investing.com South Africa
Codexis sees $261,350 stock acquisition by Opaleye management - Investing.com India
Stocks of Codexis Inc (CDXS) are poised to climb above their peers - SETE News
Major Shareholder Makes Bold Move with Codexis Stock Purchase! - TipRanks
Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Advances - GuruFocus.com
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Codexis grants equity to new hires under inducement plan - Investing.com India
New Hires at Codexis Receive Significant Equity Compensation Package - StockTitan
FY2025 EPS Estimates for Codexis Raised by Cantor Fitzgerald - Defense World
Codexis sees $172,273 stock purchase by Opaleye management - Investing.com
Codexis sees $172,273 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Things To Consider Before Buying Codexis Inc (NASDAQ: CDXS) - Stocks Register
Codexis at TD Cowen Conference: Enzymatic Innovation in siRNA Manufacturing - Investing.com
This trade activity should not be overlooked: Codexis Inc (CDXS) - SETE News
Codexis stock touches 52-week low at $2.55 amid market challenges - Investing.com Australia
Codexis Inc: Is CDXS Stock Worth Buying? - Stocks Register
Investor Network: Codexis, Inc. to Host Earnings Call - ACCESS Newswire
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Codexis (NASDAQ:CDXS investor three-year losses grow to 84% as the stock sheds US$93m this past week - Simply Wall St
When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable? - Yahoo Finance UK
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Codexis, Inc. (NASDAQ:CDXS) Q4 2024 Earnings Call Transcript - Insider Monkey
Codexis shares tumble as Q4 results miss estimates, outlook disappoints - Investing.com India
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... - Yahoo Finance
Codexis Reports 2024 Results, Eyes Growth in 2025 - TipRanks
Codexis: Balancing Revenue Shortfalls and Strategic Advances Amid Cautious Optimism - TipRanks
Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results - GlobeNewswire
Codexis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Codexis Q4 2024 misses earnings, stock slips By Investing.com - Investing.com South Africa
Earnings call transcript: Codexis Q4 2024 misses earnings, stock slips - Investing.com
Codexis: Q4 Earnings Snapshot - The Advocate
Codexis shares tumble as Q4 results miss estimates, outlook disappoints By Investing.com - Investing.com Australia
Codexis, Inc. to Host Earnings Call - ACCESS Newswire
Codexis Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Codexis announces the approval of equity grants for new employees - MSN
Codexis (CDXS) to Release Quarterly Earnings on Wednesday - Defense World
Codexis to Participate in TD Cowen 45th Annual Health Care Conference - The Manila Times
Jordan Seigel - The Globe and Mail
Exclusive: Codexis Unveils Future Roadmap at Major Healthcare Conference - StockTitan
Baillie Gifford & Co. Sells 119,775 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Synthetic Biology Market Top Companies StudyBota Biosciences - openPR
abrdn plc Reduces Stake in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Strategic Talent Investment: Codexis Awards 66.5K Shares in Employee Equity Package - StockTitan
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):